Tremelimumab

From FeedX

Enter your search terms Web feedx.net Submit search form

• bonnet_carre_spillway center_elementary_school_georgia greatandhra wwe_fire pedro_martinez tremelimumab angryjournalist_com billy_joel_s_wife hser_nay_moo bby

[edit] Overcoming immunologic tolerance to melanoma: targeting CTLA-4 ...

24 November 2008, by Ribas A One agent under investigation is tremelimumab (CP-675206), a monoclonal antibody that has been demonstrated to be a safe and efficacious treatment in patients with malignant melanoma. Results of a phase I clinical trial suggested that a ...

[edit] Pfizer's Ills And Cures In 2008 - Trading Markets (press release)

22 November 2008, by

[edit] CTLA4 blockade with ipilimumab to treat relapse of malignancy ...

20 November 2008, by Bashey A, Medina B, Corringham S, Pasek M, Carrier E, Vrooman L, Lowy I, Solomon SR, Morris LE, Holland HK, Mason JR, Alyea EP, Soiffer RJ, Ball ED 1: Blood. 2008 Oct 30. [Epub ahead of print]. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Bashey A, Medina B, Corringham S, Pasek M, Carrier E, Vrooman L, Lowy I, ...

[edit] Overcoming immunologic tolerance to melanoma: targeting CTLA-4 ...

19 November 2008, by Weber J Pending results from registration studies with ipilimumab and lessons learned from registration studies conducted with tremelimumab will help to define the role of anti-CTLA-4 blockade in the treatment of metastatic melanoma. ...

[edit] CTLA4 blockade with ipilimumab to treat relapse of malignancy ...

1 November 2008, by Bashey A, Medina B, Corringham S, Pasek M, Carrier E, Vrooman L, Lowy I, Solomon SR, Morris LE, Holland HK, Mason JR, Alyea EP, Soiffer RJ, Ball ED CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood. 2008 Oct 30;. Authors: Bashey A, Medina B, Corringham S, Pasek M, Carrier E, Vrooman L, Lowy I, Solomon SR, ...

[edit] CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to ...

25 October 2008, by Liakou CI, Kamat A, Tang DN, Chen H, Sun J, Troncoso P, Logothetis C, Sharma P CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci US A. 2008 Sep 30;105(39):14987-92. Authors: Liakou CI, Kamat A, Tang DN, Chen H, ...

[edit] Anti-Cytotoxic T-Lymphocyte Antigen-4 Antibody: The First in an ...

8 October 2008, by Fong L, Small EJ Antibodies (ipilimumab and tremelimumab) targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4), an inhibitory molecule on T cells, represent the vanguard of these new drugs. Design: We performed a systematic review of the clinical studies ...

[edit] The art of antibody process development.

4 October 2008, by Steinmeyer DE, McCormick EL The art of antibody process development. Drug Discov Today. 2008 Jul;13(13-14):613-8. Authors: Steinmeyer DE, McCormick EL. Biopharmaceutical drug development is an intricate path that spans a dozen years from discovery through ...

[edit] New response criteria proposed for immunotherapies.

30 September 2008, by Tuma RS Related Articles. New response criteria proposed for immunotherapies. J Natl Cancer Inst. 2008 Sep 17;100(18):1280-1. Authors: Tuma RS. PMID: 18780859 [PubMed - indexed for MEDLINE]

[edit] Gateways to clinical trials.

24 September 2008, by Tomillero A, Moral MA ... Taxus, Temsirolimus, Tocilizumab, Tolevamer potassium sodium, Tremelimumab, TTP-889; Uracil; V-260, Valsartan/amlodipine besylate, Vardenafil hydrochloride hydrate, Varenicline tartrate, Varespladib, Vitespen, Voclosporin, VX-001; ...

[edit] Quietly, melanoma treatment CTLA-4 antibody died

16 May 2008, by Quietly, melanoma treatment CTLA-4 antibody died Posted May 16th, 2008 by InteractMD CTLA-4 antibody Heme/Onc melanoma Pfizer tremelimumab Warren Buffett This came from a drug rep and a "meta" conversation about industry, not content, I had with the person. I usually try to yank a few chains with news I have reported on here, then ask about job security, which hasn't been great for them. The way I see them, they are my patients too. I have redefined the whole dynamic by not taking their

[edit] Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma (5/2008, 7thSpace)

11 May 2008, by ipugef Administration of CTLA4-blocking antibody tremelimumab to patients -- results with long-lived tumor responses. T-cell activation and memory markers served as the only readout of the pharmacodynamic effects of this antibody in peripheral blood.

[edit] Pfizer Announces Discontinuation of Phase III Clinical Trial for Patients with Advanced Melanoma (Business Wire)

2 April 2008, by NEW YORK----Pfizer Inc announced today the discontinuation of a Phase III clinical trial , of single-agent tremelimumab in patients with advanced melanoma, after the review of interim data showed that the trial would not demonstrate superiority to standard chemotherapy.

[edit] All Tremelimumab messages

14 November 2007, by Good Friend I checked out Wikipedia for this drug as well as other cites, it appears that Tremelimumab in the trial process has been called similar names. Also, I believe it is used in combination with another vaccine. My friend saw his oncologist ...